Innoviva to Participate in the Citi 2024 Global Healthcare Conference
Innoviva to Participate in the Citi 2024 Global Healthcare Conference
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.BURLINGAME, Calif.--(BUSINESS WIRE)--Nov. 26, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Citi 2024 Global Healthcare Conference in Miami, FL on Thursday, December 5, 2024 at 8:45 a.m. Eastern Time.
加利福尼亚州伯灵游戏--（商业信息）--2024年11月26日--innoviva, Inc.（纳斯达克：INVA）（"innoviva"或"公司"），是一家多元化控股公司，拥有核心特许权使用费投资组合、领先的重症护理和传染病平台（称为innoviva Specialty Therapeutics（"IST"））以及在医疗资产方面的战略投资组合。今天宣布，首席执行官Pavel Raifeld将于2024年12月5日周四在佛罗里达州迈阿密的花旗2024全球医疗会议上参加一场炉边聊天，会议时间为东部时间上午8:45。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at . The webcast will be available for replay for 90 days following the event.
可以在公司的官方网站的“投资者关系”部分的“事件与演示”下访问炉边谈话的现场直播网络广播。该网络广播将在活动结束后可进行90天的回放。
About Innoviva
关于Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
Innoviva是一家多元化控股公司，拥有核心的特许权使用费投资组合，领先的重症护理和传染病平台称为Innoviva Specialty Therapeutics（“IST”），以及在医疗健康资产方面的战略投资组合。Innoviva的特许权使用费投资组合包括与格兰素史克集团（“GSK”）合作的呼吸道资产。Innoviva有权从GSk获得RELVAR/BREO ELLIPTA和ANORO ELLIPTA的销售特许权使用费。Innoviva的其他创新医疗资产包括来自对Entasis Therapeutics的收购的传染病和重症护理资产，包括XACDURO（注射用舒巴坦；注射用杜洛巴坦），已联合包装用于经批准的以静脉注射治疗成人由可感染的阿西奈特巴克特复杂物引起的医院获得性细菌性肺炎和呼吸机相关性细菌性肺炎，以及目前正在开发的无并发症淋病治疗的研究性药物zoliflodacin，和拉霍亚制药公司，其中包括GIAPREZA（血管收缩素II），批准用于提高成人在出现脓毒症或其他分布性休克情况下的血压以及XERAVA（eravacycline），用于治疗成人的复杂腹腔感染。
ANORO, RELVAR and BREO are trademarks of the GSK group of companies.
ANORO、RELVAR和BREO是GSk集团公司的商标。
View source version on businesswire.com:
在businesswire.com上查看源版本：
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Innoviva，Inc。
大卫·帕蒂
企业通讯
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
投资者和媒体:
阿哥特合伙人。
（212）600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
来源：innoviva公司。
译文内容由第三方软件翻译。
